Figure 3.

SchB alleviates the stemness of cancer stem-like cells. Cancer stem-like cells (NCI-H460-CSCs and H661-CSCs) were treated with 10, 20 or 40 µmol/l SchB and the control group was treated with PBS. (A) Flow cytometry was used to evaluate the number of CD133⁺ cells. (B) CD133, CD44, Oct-4 and Bmi-1 expression was tested by western blot analysis. (C) Sphere-forming ability of cancer stem-like cells was estimated by sphere-forming assay. Scale bar, 25 µm. All experimental data are shown as the mean ± SD (n=3). Differences were analyzed by one-way ANOVA with Tukey's correction. *P<0.05, **P<0.01 vs. control. SSC, side scatter; SchB, Schisandrin B; Oct-4, octamer-binding transcription factor 4; Bmi-1, B lymphoma Mo-MLV insertion region 1 homolog.